Lipid tx cuts cardiovascular risk with type 1 diabetes

Lipid tx cuts cardiovascular risk with type 1 diabetes

(HealthDay)—The risk of cardiovascular disease (CVD) and cardiovascular death is 22 to 44 percent lower among individuals with type 1 diabetes treated with lipid-lowering therapy (LLT), according to a study published online April 18 in Diabetes Care.

Christel Hero, from the University of Gothenburg in Sweden, and colleagues used the Swedish National Diabetes Register to identify 24,230 individuals (2006 to 2008) with type 1 diabetes without a history of CVD. The cohort included 5,387 patients treated with LLT (97% statins) and 18,843 untreated, propensity-matched controls. All were followed through December 2012 (mean follow-up, six years).

The researchers found that the propensity score balanced all 32 covariates, with no differences between treated and untreated patients after accounting for propensity score. For treated compared with untreated patients, the hazard ratio for cardiovascular death was 0.6; all-cause death, 0.56; fatal/nonfatal stroke, 0.56; fatal/nonfatal acute myocardial infarction, 0.78; fatal/nonfatal coronary heart disease, 0.85; and fatal/nonfatal CVD, 0.77.

"This observational study shows that LLT is associated with 22 to 44 percent reduction in the risk of CVD and among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes," conclude the authors.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Diabetes Care

Copyright © 2016 HealthDay. All rights reserved.

Citation: Lipid tx cuts cardiovascular risk with type 1 diabetes (2016, April 22) retrieved 24 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Intensive diabetes therapy cuts CVD incidence by 30 percent


Feedback to editors